HDAC5/HDAC9 Antibody

What are HDAC5 and HDAC9, and how do they function in cellular processes?

HDAC5 and HDAC9 are class IIa histone deacetylases responsible for removing acetyl groups from lysine residues on the N-terminal part of core histones (H2A, H2B, H3, and H4). This deacetylation provides a tag for epigenetic repression and plays critical roles in transcriptional regulation, cell cycle progression, and developmental events. These enzymes act via the formation of large multiprotein complexes and are involved in muscle maturation by repressing transcription of myocyte enhancer factors such as MEF2C .

HDAC5 is known to shuttle between the nucleus and cytoplasm during muscle differentiation, allowing the expression of myocyte enhancer factors, while HDAC9 is broadly expressed with highest levels in brain, heart, muscle, and testis . Importantly, both enzymes function as signal-responsive regulators that coordinate gene expression with environmental cues.

What are the structural characteristics of HDAC5 and HDAC9?

Researchers have constructed human HDAC5 and HDAC9 protein models using human HDAC4 (PDB:2VQM_A) as a template through homology modeling approaches . A distinctive feature of class IIa HDACs, including HDAC5 and HDAC9, is the presence of a Zinc Binding Domain (ZBD). This domain consists of a β-hairpin surrounded by two antiparallel β-strands, forming a pocket-like structure that accommodates a "structural" zinc ion .

The ZBD is extremely flexible, and in HDAC4 (closely related to HDAC5/HDAC9), the oxidation of cysteines involved in Zn²⁺ coordination is sufficient to free the metal, causing opening and deconstruction of the domain . This domain's proximity to the active site makes the class IIa HDACs' catalytic site more accessible than that of class I HDACs, which affects their enzymatic activity and interaction with inhibitors.

How are HDAC5 and HDAC9 regulated in different cellular contexts?

Multiple regulatory mechanisms control HDAC5 and HDAC9 activity:

• Subcellular localization: Nuclear/cytoplasmic transport is a key regulatory mechanism. During muscle differentiation, HDAC5 shuttles into the cytoplasm, allowing the expression of myocyte enhancer factors .

• Chromatin binding dynamics: Even within the nucleus, HDAC5 can be subjected to regulations that affect its ability to bind chromatin. FRAP experiments have identified different nuclear pools of class IIa HDACs with distinct binding characteristics .

• Protein-protein interactions: The discharge of class IIa HDACs from their transcriptional partners is an important step in modulating their repressive ability. HDAC5 mutants carrying an inactive Nuclear Export Signal (NES) cannot exit the nuclei but are also unable to impact muscle cell differentiation .

• Signal-responsive modifications: Post-translational modifications, particularly phosphorylation, regulate both the localization and activity of these enzymes in response to various cellular signals.

What are the optimal conditions for using HDAC5/HDAC9 antibodies in Western blot applications?

Based on validated protocols, the following conditions are recommended for Western blot applications:

For HDAC9 antibodies:

• Dilution range: 1:1000-1:4000 (sample-dependent)

• Predicted molecular weight: 111 kDa

• Observed molecular weight: 130-140 kDa

• Positive detection in: HeLa, Daudi, HepG2, Raji, K-562, and Ramos cells

• Sample preparation: Whole cell lysates (typically 20 μg protein loading)

• Secondary antibody: Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 dilution

For HDAC5 antibodies:

• Applications: Western blot, IHC-FoFr, IHC-P, ICC/IF

• Reactivity: Mouse, Human samples

• Immunogen: Synthetic Peptide within Human HDAC5

• Alternative names to check specificity: KIAA0600, HD5, Antigen NY-CO-9

How can I validate the specificity of HDAC5/HDAC9 antibodies for my research?

Multiple validation strategies should be employed to ensure antibody specificity:

• Knockout/Knockdown Validation: Test antibodies on samples from knockout models or after siRNA-mediated knockdown. The antibody should recognize the target protein in wild-type samples but show diminished or absent signal in knockout/knockdown samples .

• Peptide Competition Assay: Preincubate the antibody with the immunizing peptide before application. A specific antibody will show significantly reduced signal when blocked with its target peptide .

• Multiple Cell Line Analysis: Verify consistent signal at the expected molecular weight across various cell lines with known expression patterns .

• Isotype Controls: Include appropriate isotype-matched control antibodies to identify non-specific binding.

• Molecular Weight Verification: Confirm that the observed band corresponds to the predicted molecular weight (accounting for post-translational modifications).

• Cross-Reactivity Testing: For closely related proteins like HDAC5 and HDAC9, verify that each antibody specifically detects only its intended target.

What is the recommended protocol for HDAC5/HDAC9 immunoprecipitation studies?

For HDAC9 immunoprecipitation, the following protocol has been validated:

• Sample Preparation: Prepare 0.35 mg of whole cell lysate (e.g., from K-562 cells)

• Antibody Incubation: Use HDAC9 antibody at 1/30 dilution (approximately 2μg antibody per 0.35mg lysate)

• Immunoprecipitation Process:

  • Incubate lysate with antibody overnight at 4°C

  • Add protein A/G beads and incubate for 1-2 hours

  • Wash beads thoroughly to remove non-specific binding

• Western Blot Detection: Perform western blot on the immunoprecipitate

• Controls: Include parallel immunoprecipitation with isotype-matched control antibody (e.g., Rabbit monoclonal IgG)

• Blocking Buffer: 5% NFDM/TBST

• Detection: VeriBlot for IP Detection Reagent (HRP) or equivalent secondary antibody optimized for IP to minimize detection of denatured IgG

For co-immunoprecipitation studies investigating protein interactions, as demonstrated with HDAC9 and ATDC, similar principles apply but with adjustment for detecting the interacting protein .

How should I optimize immunohistochemistry protocols for HDAC5/HDAC9 detection in tissue samples?

For optimal immunohistochemical detection of HDAC5/HDAC9:

• Tissue Preparation:

  • Formalin/PFA-fixed paraffin-embedded sections

  • Section thickness: typically 4-5 μm

• Antigen Retrieval:

  • Heat-mediated antigen retrieval using Bond™ Epitope Retrieval Solution 2 (pH 9.0)

  • Critical step for exposing epitopes masked by fixation

• Antibody Dilution and Incubation:

  • Primary antibody: 1:1000 dilution (approximately 1.10 μg/ml)

  • Incubation time: overnight at 4°C or 1-2 hours at room temperature

• Detection System:

  • Rabbit-specific IHC polymer detection kit HRP/DAB

  • Counterstain: Hematoxylin for visualization of tissue architecture

• Controls:

  • Positive control: Include tissue known to express the target protein

  • Negative control: Substitute primary antibody with PBS or isotype control

• Optimization Strategies:

  • Test multiple antigen retrieval methods (citrate buffer vs. EDTA-based)

  • Perform antibody titration to determine optimal concentration

  • Adjust incubation times and temperatures

  • Evaluate different detection systems for signal-to-noise optimization

For immunofluorescence applications, similar principles apply with appropriate fluorophore-conjugated secondary antibodies and counterstains.

How do HDAC5 and HDAC9 contribute to cardiac hypertrophy and heart development?

HDAC5 and HDAC9 serve as crucial negative regulators of cardiac hypertrophy and play important roles in heart development:

• Suppression of Pathological Hypertrophy: Mice lacking either HDAC5 or HDAC9 develop profoundly enlarged hearts in response to pressure overload from aortic constriction or constitutive cardiac activation of calcineurin, a transducer of cardiac stress signals .

• Pathway Specificity: Interestingly, mice lacking either HDAC5 or HDAC9 show a normal hypertrophic response to chronic β-adrenergic stimulation, suggesting these HDACs specifically modulate distinct cardiac stress response pathways .

• Developmental Functions: While single knockouts have normal cardiac structure at birth, compound mutant mice lacking both HDAC5 and HDAC9 show:

  • High embryonic and postnatal mortality

  • Ventricular septal defects

  • Thin-walled myocardium

  • Severe growth retardation in survivors

• Functional Redundancy: The data demonstrate overlapping functions between HDAC5 and HDAC9 in cardiac development, as shown in this genotype distribution table from HDAC5/HDAC9 heterozygous matings:

The significant underrepresentation of double null mice (1% observed vs. 6.25% expected) highlights their critical developmental roles .

What is the role of HDAC5 in cancer progression and metastasis?

HDAC5 demonstrates complex and context-dependent roles in cancer:

• Expression in Malignancies: PCR and immunohistochemical analyses show high HDAC5 expression in the cytoplasm of various malignant epithelial cells .

• Metastasis Promotion: HDAC5 expression positively correlates with:

  • Distant metastasis

  • Lymph node metastasis

  • Intrahepatic metastasis in hepatocellular carcinoma (HCC)

• Molecular Mechanisms in Invasion:

  • In gastric cancer: Enhances invasiveness by stimulating PKC/MMP9 pathways

  • In HCC: Involved in Tbx3-mediated EMT and metastasis

  • In glioma: Promotes doxorubicin-induced EMT, potentially contributing to chemoresistance

• Proliferation Regulation:

  • Pro-proliferative in colorectal cancer (via DLL4 upregulation)

  • Promotes osteosarcoma cell proliferation (Twist1-dependent)

  • Increases glioma cell proliferation (via Notch1)

  • Activates HCC proliferation (by inducing Six1 expression)

• Dual Functionality: Surprisingly, HDAC5 can inhibit proliferation in certain contexts:

  • In urothelial carcinoma, elevated HDAC5 suppresses cell proliferation via TGF-β, while simultaneously promoting EMT

• Diagnostic Potential: HDAC5 has been detected in the blood of patients with colorectal and breast cancers but not in healthy subjects, suggesting utility as a diagnostic biomarker with 96.3% specificity in distinguishing CRC patients from healthy individuals .

How does HDAC5 regulate angiogenesis in endothelial cells?

HDAC5 functions as a negative regulator of angiogenesis through multiple mechanisms:

• Repression of Pro-angiogenic Pathways:

  • Silencing HDAC5 increases endothelial cell migration, sprouting, and tube formation

  • Overexpression of HDAC5 decreases sprout formation in endothelial cells

• Transcriptional Regulation:

  • HDAC5's antiangiogenic activity requires nuclear localization

  • Functions independently of MEF2 binding and deacetylase activity

  • Directly binds to and represses key angiogenic gene promoters

• Target Gene Regulation: Microarray analysis identified critical HDAC5-repressed genes:

  • Fibroblast growth factor 2 (FGF2)

  • Guidance factor Slit2

  • Other angiogenic modulators

• Functional Validation:

  • Antagonizing FGF2 or Slit2 blocks the pro-angiogenic effects of HDAC5 knockdown

  • Chromatin immunoprecipitation confirms HDAC5 directly binds to FGF2 and Slit2 promoters

• In Vivo Significance: Matrigel plug assays demonstrated:

  • HUVECs with HDAC5 knockdown promote blood vessel infiltration in vivo

  • Increased hemoglobin content in plugs with HDAC5-depleted cells

  • Enhanced functional perfusion of newly formed vessels

• Contrasting Roles within HDAC Family: Unlike HDAC5, silencing of HDAC7 and HDAC9 blocked angiogenesis, highlighting the diverse and specific functions even within the same enzyme class .

This anti-angiogenic function suggests potential therapeutic applications where HDAC5 inhibitors might improve therapeutic angiogenesis after ischemia, while HDAC5 activators could potentially block pathologic angiogenesis .

What are the challenges in developing selective inhibitors for HDAC5 and HDAC9?

Developing selective inhibitors for HDAC5 and HDAC9 presents several significant challenges:

• Structural Homology: High structural similarity among class IIa HDACs complicates selective targeting. Researchers have had to use HDAC4 as a template for homology modeling of HDAC5 and HDAC9 due to the lack of specific crystal structures .

• Unique Catalytic Site Features: The class IIa HDACs possess distinct active site characteristics:

  • A Zinc Binding Domain (ZBD) adjacent to the active site

  • More accessible catalytic site compared to class I HDACs

  • Lack of an efficient hydrophilic tunnel for acetate release

• Dynamic Structural Elements: The ZBD is extremely flexible, and oxidation of coordinating cysteines can disrupt the domain structure, potentially affecting inhibitor binding .

• Catalytic Activity Considerations: Class IIa HDACs have significantly lower intrinsic deacetylase activity compared to class I HDACs, complicating activity-based inhibitor development and screening.

• Non-Catalytic Functions: HDAC5 and HDAC9 have multiple functions beyond deacetylase activity, including protein-protein interactions and scaffolding roles. Inhibitors targeting only the catalytic site might not effectively block all relevant biological activities.

Recent modeling and inhibitor design approaches have made progress:

• Using HDAC4 (PDB:2VQM_A) as a template for homology modeling

• Validating models through molecular dynamic simulations

• Identifying compounds with dual HDAC5/HDAC9 inhibition potential (CHEMBL2114980 and CHEMBL217223)

How can I distinguish between the specific functions of HDAC5 versus HDAC9 in my experimental system?

To delineate the distinct functions of these highly similar enzymes:

• Selective Knockdown/Knockout Approaches:

  • Use siRNA or CRISPR targeting specific regions unique to each protein

  • Compare phenotypes between HDAC5, HDAC9, and double knockdowns/knockouts

  • Example: In endothelial cells, HDAC5 silencing promotes angiogenesis while HDAC9 silencing blocks it

• Protein Interaction Analysis:

  • Perform immunoprecipitation followed by mass spectrometry to identify unique binding partners

  • HDAC9 specifically interacts with ATDC, while HDAC7 does not, suggesting distinct interaction profiles

  • Different interaction partners may indicate divergent functions

• Subcellular Localization Studies:

  • Monitor localization of each protein under various stimuli

  • HDAC5 shuttling between nucleus and cytoplasm is a key regulatory mechanism

• Tissue and Context Specificity:

  • Compare expression and function across multiple cell types

  • HDAC9 is broadly expressed with highest levels in brain, heart, muscle, and testis

  • Different expression patterns may indicate tissue-specific roles

• Response to Specific Stimuli:

  • Test responses to various signaling activators and inhibitors

  • Mice lacking either HDAC5 or HDAC9 show differential responses to various cardiac stress signals

• Genetic Rescue Experiments:

  • Attempt to rescue HDAC5 knockout/knockdown with HDAC9 expression and vice versa

  • Partial rescue indicates shared functions, while failed rescue highlights unique roles

• Chimeric Protein Analysis:

  • Create chimeras swapping domains between HDAC5 and HDAC9

  • Identify which domains are responsible for unique functions

What are the key considerations when interpreting contradictory findings about HDAC5/HDAC9 expression in different cancer types?

The literature contains contradictory findings regarding HDAC5/HDAC9 roles in cancer, requiring careful interpretation:

• Context-Dependent Functions: HDAC5 demonstrates opposing roles depending on cellular context:

  • Promotes proliferation in colorectal cancer, osteosarcoma, glioma, and HCC

  • Suppresses proliferation in urothelial carcinoma (while still promoting EMT)

• Cancer Type Specificity: HDAC5 expression patterns vary dramatically:

  • Elevated in breast cancer (luminal A and B subtypes)

  • Found in blood of CRC patients but not healthy subjects

  • Significantly downregulated in glioblastoma multiforme (2.38-fold decrease)

• Prognostic Implications: Expression can predict opposite outcomes:

  • HDAC5: High expression correlates with extended disease-free survival in glioma (HR:0.43)

  • HDAC9: High expression associates with reduced DFS in glioma (HR:1.5)

• Methodological Considerations:

  • Detection method differences (protein vs. mRNA quantification)

  • Sample types (cell lines vs. patient tissues)

  • Subcellular localization analysis (nuclear vs. cytoplasmic measurement)

  • Total protein vs. phosphorylated/modified forms

• Study Design Factors:

  • Patient population heterogeneity

  • Cancer stage differences

  • Treatment status variations

  • Statistical power limitations

• Biological Complexity: The contradictions likely reflect genuine biological complexity rather than simply experimental artifacts, as explicitly stated in the literature: "These conflicting findings imply that HDAC5 exhibits dual functions in cancer development" .

When designing experiments to resolve contradictions, researchers should:

• Use multiple detection methods

• Analyze both mRNA and protein levels with appropriate controls

• Specify cancer subtype, stage, and genetic background

• Consider subcellular localization and post-translational modifications

• Include functional assays beyond simple expression analysis

What controls should be included in HDAC5/HDAC9 knockdown or overexpression experiments?

Rigorous experimental design requires comprehensive controls:

For Knockdown Experiments:

• Non-targeting Control: Include scrambled/non-targeting siRNA with similar chemical properties to verify that observed effects are specific to target depletion rather than transfection effects .

• Validation of Knockdown Efficiency:

  • Western blot to confirm protein reduction

  • qRT-PCR for mRNA levels

  • Ideally showing dose-dependent effects

• Multiple siRNA Sequences: Use at least two independent siRNAs targeting different regions to rule out off-target effects.

• Single and Combined Knockdowns: When studying potentially redundant proteins like HDAC5 and HDAC9, include:

  • HDAC5 knockdown alone

  • HDAC9 knockdown alone

  • Combined HDAC5/HDAC9 knockdown

  • This approach revealed redundant cardiac developmental roles in mouse models

• Rescue Experiments: Re-express siRNA-resistant versions of the target gene to confirm phenotype specificity.

For Overexpression Experiments:

• Empty Vector Control: Cells transfected with the same expression vector lacking the gene insert.

• Inactive Mutant Controls: Express catalytically inactive or functionally compromised versions (e.g., nuclear localization mutants for HDAC5).

• Expression Verification:

  • Western blot confirmation of increased protein

  • Immunofluorescence for proper subcellular localization

For Both Approaches:

• Functional Readouts:

  • Histone acetylation status at known target genes

  • Expression analysis of established target genes

  • Phenotypic assays specific to the process being studied

• Time Course Analysis: Examine effects at multiple time points to distinguish primary from secondary effects.

• Context Controls: Test in multiple relevant cell types to determine context specificity.

What experimental approaches can reveal the transcriptional targets of HDAC5 and HDAC9?

To identify and validate transcriptional targets:

• Genome-wide Expression Profiling:

  • RNA-seq or microarray analysis following knockdown/overexpression

  • This approach identified FGF2 and Slit2 as HDAC5 targets in endothelial cells

  • Compare acute vs. sustained manipulation to identify direct targets

• Chromatin Immunoprecipitation (ChIP) Approaches:

  • ChIP-seq to map genome-wide binding sites

  • ChIP-qPCR to validate binding at specific promoters

  • Example: ChIP assays demonstrated HDAC5 binding to FGF2 and Slit2 promoters

• Functional Validation:

  • Antagonize identified targets to reverse phenotypes

  • Blocking FGF2 or Slit2 reduced sprout induction in response to HDAC5 siRNA

  • Overexpress targets to phenocopy HDAC depletion effects

• Reporter Assays:

  • Test promoter activity using luciferase reporters

  • Compare wild-type vs. mutated binding sites

  • Assess responsiveness to HDAC5/9 manipulation

• Integrated Multi-omics:

  • Combine transcriptomics with:

    • ChIP-seq data

    • Histone acetylation mapping (H3K27ac, H3K9ac)

    • Chromatin accessibility (ATAC-seq)

  • Integrate data to distinguish direct vs. indirect regulation

• Protein Complex Analysis:

  • Identify transcriptional complexes containing HDAC5/HDAC9

  • Determine co-regulators that confer target specificity

  • Map multiprotein complex assembly on specific promoters

• Domain-specific Manipulation:

  • Express truncated proteins or domain mutants

  • Identify domains required for target gene regulation

  • Example: HDAC5's antiangiogenic activity required nuclear localization but was independent of deacetylase activity

These approaches, when combined, provide comprehensive understanding of the transcriptional networks regulated by HDAC5 and HDAC9.